PROCEPT BioRobotics PRCT 深 沪
等待开盘 07-26 09:30:00 美东时间
55.72
-2.920
-4.98%
华盛通- 最 高58.87
- 今 开58.28
- 成交量 389.13万股
- 最 低 51.00
- 昨 收 58.64
- 总市值 30.83亿
- 52周最高 103.8099
- 市盈率 静 --
- 换手率 7.03%
- 52周最低 47.0401
- 委 比 -38.40%
- 总股本 5532.87万
- 历史最高 103.8099
- 量 比 3.52
- 振 幅 13.42%
- 历史最低 15.38
- 每 手 1
- 风险率 13.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Procept BioRobotics down after CEO retirement
Shares of Procept BioRobotics (NASDAQ:PRCT) fell ~9% on Friday after the surgical robotics company announced that its CEO, Reza Zadno, would retire effective Sept. 1, and Larry Wood, a member of the b...
07-25 23:23
PROCEPT BioRobotics Announces Preliminary Q2 Revenue Of ~$79.2M
SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) ("the Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology,
07-25 06:05
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
PROCEPT BioRobotics announced that Larry L. Wood will join as president and CEO on September 2, 2025, succeeding Reza Zadno, who will retire. The company pre-announced Q2 2025 revenue of approximately $79.2 million, reflecting a 48% year-over-year growth. Wood brings over 40 years of experience in the medical technology industry, including leadership roles at Edwards Lifesciences. Zadno, who led the company since 2020, expressed pride in the team...
07-24 22:00
PROCEPT BioRobotics Completes Three Prostate Cancer Procedures In WATER IV Prostate Cancer Trial In ASC Using Aquablation Therapy
PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that three prostate cancer
07-23 20:05
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
PROCEPT BioRobotics Corporation announced the successful completion of three prostate cancer procedures in an Ambulatory Surgery Center (ASC) using Aquablation® therapy, part of the WATER IV PCa Trial. The trial compares Aquablation therapy, a minimally invasive, image-guided procedure, with radical prostatectomy for localized prostate cancer treatment. Conducted by Dr. Rahul Mehan, the procedures marked the first prostate cancer treatments in an...
07-23 12:00
PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025
PROCEPT BioRobotics Corporation将发布2025年第二季度财务报告，并于8月6日下午4:30举办电话会议。投资者可通过提供的链接参加网络直播或录音。公司专注于开发泌尿外科机器人解决方案，其HYDROS Robotic System是唯一AI驱动的机器人技术，提供Aquablation治疗，适用于前列腺肥大相关下尿路症状患者。
07-21 20:03
Morgan Stanley Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $68
Morgan Stanley analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $71 to $68.
07-15 21:11
Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
PROCEPT BioRobotics announced that Aquablation therapy has been assigned a Category I CPT code (52XX1) effective January 1, 2026, replacing the existing Category III code 0421T. This milestone reflects the therapy's clinical value and adoption, offering durable symptom relief for BPH with minimal sexual side effects. The new code has a proposed Medicare payment rate of $540, slightly higher than TURP's $529. Aquablation, a robotic-assisted, ultra...
07-15 01:15
Oppenheimer Initiates Coverage On PROCEPT BioRobotics with Perform Rating
Oppenheimer analyst Suraj Kalia initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Perform rating.
07-07 21:52
PROCEPT BioRobotics to Present at Investor Conferences
PROCEPT BioRobotics ( ($PRCT) ) has provided an announcement. PROCEPT BioRoboti...
04-25 21:29
